Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)
Public ClinicalTrials.gov record NCT00206219. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomised, Stratified, Parallel-Group, Multi-Centre, Comparative Study of ZD1839 (Iressa®) 250 Mg and 500 Mg Versus Methotrexate for Previously Treated Patients With Squamous Cell Carcinoma of the Head and Neck
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is to compare ZD1839 (250mg and 500mg) versus methotrexate in head and neck cancer in terms of overall survival.
Study identification
- NCT ID
- NCT00206219
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 477 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2003 (Type not available)
- Primary completion
- Sep 2007 (Actual)
- Completion
- Sep 2007 (Actual)
- Last update posted
- Jan 27, 2011
2003 – 2007
United States locations
- U.S. sites
- 26
- U.S. states
- 22
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | — | — |
| Research Site | Tucson | Arizona | — | — |
| Research Site | Palm Springs | California | — | — |
| Research Site | Aurora | Colorado | — | — |
| Research Site | New Haven | Connecticut | — | — |
| Research Site | Norwalk | Connecticut | — | — |
| Research Site | Miami | Florida | — | — |
| Research Site | Orlando | Florida | — | — |
| Research Site | Ormand Beach | Florida | — | — |
| Research Site | Savannah | Georgia | — | — |
| Research Site | Chicago | Illinois | — | — |
| Research Site | Des Moines | Iowa | — | — |
| Research Site | Louisville | Kentucky | — | — |
| Research Site | Baton Rouge | Louisiana | — | — |
| Research Site | Waterville | Maine | — | — |
| Research Site | Bethesda | Maryland | — | — |
| Research Site | Detroit | Michigan | — | — |
| Research Site | Omaha | Nebraska | — | — |
| Research Site | Hackensack | New Jersey | — | — |
| Research Site | Brooklyn | New York | — | — |
| Research Site | New York | New York | — | — |
| Research Site | Oklahoma City | Oklahoma | — | — |
| Research Site | Philadelphia | Pennsylvania | — | — |
| Research Site | Norfolk | Virginia | — | — |
| Research Site | Olympia | Washington | — | — |
| Research Site | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 83 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00206219, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 27, 2011 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00206219 live on ClinicalTrials.gov.